Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Washington Trust Advisors Inc.

Key Points

• Washington Trust Advisors reduced its Regeneron stake by 6.8% in the third quarter, selling 1,880 shares and retaining 25,823 shares valued at approximately $19.6 million. Institutional investors collectively own 83.31% of REGN.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and average price target of $846.28; TD Cowen recently raised its target to $980.
• Regeneron shares fell 1.7% to $805.02, while the company’s latest quarterly results exceeded expectations with $14.29 in adjusted EPS and $4.29 billion in revenue. Investors are awaiting the next earnings report amid valuation concerns and uncertainty about a potential earnings beat.

Washington Trust Advisors Inc. trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,823 shares of the biopharmaceutical company's stock after selling 1,880 shares during the period. Regeneron Pharmaceuticals comprises about 1.4% of Washington Trust Advisors Inc.'s portfolio, making the stock its 19th largest position. Washington Trust Advisors Inc.'s holdings in Regeneron Pharmaceuticals were worth $19,581,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. LCM Capital Management Inc lifted its position in shares of Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company's stock worth $467,000 after purchasing an additional 13 shares during the period. Arjuna Capital boosted its stake in shares of Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock valued at $353,000 after purchasing an additional 14 shares in the last quarter. Boyd Watterson Asset Management LLC OH boosted its stake in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company's stock valued at $840,000 after purchasing an additional 15 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company's stock valued at $645,000 after buying an additional 15 shares during the period. Finally, Aaron Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 1.5% during the first quarter. Aaron Wealth Advisors LLC now owns 1,102 shares of the biopharmaceutical company's stock valued at $851,000 after buying an additional 16 shares during the period. 83.31% of the stock is currently owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Analyst Upgrades and Downgrades

A number of analysts have weighed in on REGN shares. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. The Goldman Sachs Group lifted their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a "buy" rating in a report on Friday, July 31st. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a "sector perform" rating in a research note on Thursday, October 8th. Finally, Leerink Partners upped their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $846.28.

Regeneron Pharmaceuticals Stock Down 1.7%

NASDAQ:REGN traded down $14.07 during midday trading on Friday, reaching $805.02. 527,731 shares of the stock traded hands, compared to its average volume of 705,231. Regeneron Pharmaceuticals, Inc. has a 12-month low of $575.93 and a 12-month high of $859.34. The business has a 50-day moving average of $791.86 and a two-hundred day moving average of $723.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a market capitalization of $82.88 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 1.38 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company earned $12.81 earnings per share. The business's revenue for the quarter was up 16.7% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of the firm's stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the sale, the insider owned 47,833 shares of the company's stock, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock valued at $6,506,845 in the last 90 days. Corporate insiders own 6.97% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.